Vimarsana
Biggest News Aggregation in the World

Page 11 - Lobby Level News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lobby Level. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lobby Level Today - Breaking & Trending Today

Best afternoon teas in Singapore: Scones, sandwiches and sweet treats for high tea in the city - Vimarsana News

Best afternoon teas in Singapore: Scones, sandwiches and sweet treats for high tea in the city

The best kind of afternoons are the long, slow ones, lulled away over a pot of tea and a spread of dainty treats. If you’re nodding in agreement, it’s time to plan your next escape from your hectic week with our curation of the best afternoon teas in Singapore. We’re talking scones and lobster sandwiches, free-flow champagne and fresh brews...

Best cocktail brunches: Sip and savour your way to happy weekends - Vimarsana News

Best cocktail brunches: Sip and savour your way to happy weekends

Waking up on your own terms on the weekends is quite a splendid feeling. No morning traffic rush, no work calls and meetings to attend, and no lunchtime crowd to battle with, it’s the best time to enjoy a leisurely brunch. And when they come with cocktail programs like the ones we have rounded up for you, happy hour starts...

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2023 Congress - Vimarsana News

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

Montrouge, France, February 21, 2023 DBV Technologies to Participate in Upcoming AAAAI 2023 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology - Vimarsana News

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting - Vimarsana News

Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present detailed results from the registrational PIONEER trial of...